Ant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov 2012; two: 92233. 27. Guix M, Faber AC, Wang SE, Olivares MG, Song Y, Qu S et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 2008; 118: 2609619. 28. Pao W, Miller VA. Epidermal growth element receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: existing expertise and future directions. J Clin Oncol 2005; 23: 2556568. 29. Janne PA, Johnson BE. Impact of epidermal growth aspect receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal development factor receptor tyrosine kinase inhibitors. Clin Cancer Res 2006; 12: 4416s420s. 30. Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly efficient in preclinical lung cancer models. Oncogene 2008; 27: 4702711. 31. Zhou W, Ercan D, Chen L, Yun CH, Li D, Capelletti M et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009; 462: 1070074. 32. Wong KK. HKI-272 in non smaller cell lung cancer. Clin Cancer Res 2007; 13: s4593 4596. 33. Eskens FA, Mom CH, Planting AS, Gietema JA, Amelsberg A, Huisman H et al. A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal development element receptor 1 (EGFR) and two (HER2) tyrosine kinase within a 2-week on, 2-week off schedule in sufferers with sophisticated solid tumours. Br J Cancer 2008; 98: 805. 34. Sos ML, Rode HB, Heynck S, Peifer M, Fischer F, Kluter S et al. Chemogenomic profiling gives insights into the restricted activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation. Cancer Res 2010; 70: 86874. 35. Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in sophisticated non-small-cell lung cancer. J Clin Oncol 2005; 23: 5892899. 36. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V et al. Gefitinib in mixture with gemcitabine and cisplatin in sophisticated non-small-cell lung cancer: a phase III trial NTACT 1. J Clin Oncol 2004; 22: 77784. 37. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C et al. Gefitinib in mixture with paclitaxel and carboplatin in sophisticated non-small-cell lung cancer: a phase III trial NTACT two.Rosiglitazone J Clin Oncol 2004; 22: 78594.Schisandrin 38. Minucci S, Pelicci PG. Histone deacetylase inhibitors as well as the guarantee of epigenetic (and much more) treatments for cancer. Nat Rev Cancer 2006; 6: 381. 39. Kristensen LS, Nielsen HM, Hansen LL. Epigenetics and cancer therapy.PMID:25016614 Eur J Pharmacol 2009; 625: 13142. 40. Arnold NB, Arkus N, Gunn J, Korc M. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces development inhibition and enhances gemcitabine-induced cell death in pancreatic cancer. Clin Cancer Res 2007; 13: 186. 41. Dowdy SC, Jiang S, Zhou XC, Hou X, Jin F, Podratz KC et al. Histone deacetylase inhibitors and paclitaxel bring about synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells. Mol Cancer Ther 2006; five: 2767776. 42. Rikiishi H, Shinohara F, Sato T, Sato Y, Suzuki M, Echigo S. Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxami.